NASDAQ:THTX Theratechnologies (THTX) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free THTX Stock Alerts $1.66 +0.20 (+13.70%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.45▼$1.6650-Day Range$1.18▼$2.0152-Week Range$0.88▼$4.30Volume62,500 shsAverage Volume33,516 shsMarket Capitalization$40.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Theratechnologies alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Theratechnologies Stock (NASDAQ:THTX)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More THTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THTX Stock News HeadlinesMarch 28, 2024 | globenewswire.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformMarch 24, 2024 | investing.comTheratechnologies shifts focus, phases down preclinical researchMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 22, 2024 | globenewswire.comTheratechnologies Announces Update on its Preclinical Oncology Research ProgramMarch 21, 2024 | globenewswire.comTheratechnologies Appoints Jordan Zwick to its Board of DirectorsMarch 21, 2024 | globenewswire.comTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 29, 2024 | globenewswire.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauFebruary 27, 2024 | globenewswire.comTheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 21, 2024 | washingtonpost.comTheratechnologies: Fiscal Q4 Earnings SnapshotFebruary 21, 2024 | globenewswire.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 20, 2024 | globenewswire.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 15, 2024 | finance.yahoo.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 15, 2024 | globenewswire.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerJanuary 23, 2024 | finance.yahoo.comTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License ApplicationJanuary 19, 2024 | msn.comUpcoming FDA Decision: How likely is approval for EGRIFTA MDV?January 6, 2024 | theglobeandmail.comWill This Dual-Listed Bio-Pharma Catch New Year Action?January 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDADecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | finance.yahoo.comTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comTheratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseSee More Headlines Receive THTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/29/2024Next Earnings (Estimated)4/10/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:THTX CUSIPN/A CIK1512717 Webwww.theratech.com Phone(514) 336-7800Fax514-331-9691Employees103Year Founded1993Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net Margins-29.30% Pretax Margin-28.78% Return on EquityN/A Return on Assets-33.93% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.21 Sales & Book Value Annual Sales$81.76 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.86) per share Price / Book-1.93Miscellaneous Outstanding Shares24,200,000Free FloatN/AMarket Cap$40.17 million OptionableOptionable Beta1.31 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)President, CEO & Director Comp: $1.18MMr. Philippe Dubuc M.B.A. (Age 57)MBA, Senior VP & CFO Comp: $432.31kMr. Jocelyn Lafond L.L.M. (Age 56)LL.B., General Counsel & Corporate Secretary Comp: $316.29kDr. Christian Marsolais Ph.D. (Age 61)Senior VP & Chief Medical Officer Comp: $434.61kMr. John Leasure (Age 59)Global Commercial Officer Comp: $420.91kHon. Andre Dupras M.Sc. (Age 60)Vice President of Human Resources More ExecutivesKey CompetitorsSELLAS Life Sciences GroupNASDAQ:SLSeFFECTOR TherapeuticsNASDAQ:EFTRAcurx PharmaceuticalsNASDAQ:ACXPBiora TherapeuticsNASDAQ:BIORAcasti PharmaNASDAQ:ACSTView All CompetitorsInstitutional OwnershipNantahala Capital Management LLCBought 2,682,228 shares on 2/15/2024Ownership: 11.084%AIGH Capital Management LLCBought 2,915,906 shares on 2/12/2024Ownership: 15.368%Stifel Financial CorpSold 20,000 shares on 2/12/2024Ownership: 0.285%Worth Venture Partners LLCBought 710,551 shares on 2/9/2024Ownership: 3.746%Wealthspire Advisors LLCBought 51,250 shares on 2/7/2024Ownership: 0.212%View All Institutional Transactions THTX Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THTX shares. View THTX analyst ratings or view top-rated stocks. How have THTX shares performed in 2024? Theratechnologies' stock was trading at $1.62 on January 1st, 2024. Since then, THTX shares have increased by 2.5% and is now trading at $1.66. View the best growth stocks for 2024 here. Are investors shorting Theratechnologies? Theratechnologies saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 17,100 shares, a decrease of 35.7% from the February 29th total of 26,600 shares. Based on an average daily volume of 74,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are short sold. View Theratechnologies' Short Interest. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 10th 2024. View our THTX earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (NASDAQ:THTX) posted its earnings results on Wednesday, February, 21st. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.16. The business had revenue of $23.45 million for the quarter. During the same period in the previous year, the firm posted ($0.36) earnings per share. When did Theratechnologies' stock split? Shares of Theratechnologies reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What guidance has Theratechnologies issued on next quarter's earnings? Theratechnologies issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $87.0 million-$90.0 million, compared to the consensus revenue estimate of $91.4 million. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX). Who are Theratechnologies' major shareholders? Theratechnologies' stock is owned by many different retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (15.37%), Nantahala Capital Management LLC (11.08%), Worth Venture Partners LLC (3.75%), National Bank of Canada FI (0.47%), Stifel Financial Corp (0.29%) and Wealthspire Advisors LLC (0.21%). How do I buy shares of Theratechnologies? Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Theratechnologies have any subsidiaries? The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.Read More This page (NASDAQ:THTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.